555 Identification of Microorganisms Using Nucleic Acid Probe prn.pdf
This medical policy defines medical necessity and investigational determinations for nucleic acid testing using direct, amplified, or quantitative probe techniques (including viral load quantification) for identification of a range of microorganisms, applicable to Commercial and Medicare members of Blue Cross Blue Shield Massachusetts. It also provides coding guidance, inpatient preauthorization requirements, and lists CPT codes considered medically necessary versus investigational.
Clarified coding information.
Mycoplasma genitalium added to list of medically necessary nucleic acid testing.
Policy updated with literature review through April 4, 2025; references added; policy statements unchanged.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.